Results 71 to 80 of about 5,080 (193)

Lecanemab for Alzheimer\u27s Disease

Lecanemab is a novel drug developed by Sisai and Biogen aimed at treating Alzheimer’s Disease. Alzheimer’s Disease is characterized by the misfolding and accumulation of neurotoxic amyloid-beta plaques in the brain, leading to neuronal cell death and ...
Zhu, Bohan, Abossi, Yasmine
core   +1 more source

Lecanemab Planning

Neurology Clinical Practice
Approximately 6.9 million American individuals have Alzheimer dementia and 50% have mild disease. Lecanemab, an approved antiamyloid antibody, is associated with modest reduction in functional decline in patients with mild dementia or mild cognitive impairment.
Shane, Rita, Kremen, Sarah, Tan, Zaldy S., Tran, Hai, Tu, Thanh G., Sicotte, Nancy L.   +5 more
openaire   +4 more sources

Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis

Alzheimer’s Research & Therapy
Background and objectives Lecanemab (Leqembi®) has been approved for the treatment of early Alzheimer’s disease (AD) patients. However, the safety and efficacy of lecanemab in clinical practice in Asia population remain unclear.
Jia Shang, Siyan Zhong, Li Shang, Qingze Zeng, Shuai Zhao, Xiao Luo, Kaicheng Li, Xinyi Zhang, Peiyu Huang, Yaping Yan, Zhirong Liu, Baorong Zhang, Yanxing Chen   +12 more
doaj   +1 more source

Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications

Neuroprotection, Volume 4, Issue 3, Page 229-247, September 2026.
Circadian dysregulation contributes to Alzheimer's disease through sleep disruption, clock‐gene dysfunction, neuroinflammation, impaired proteostasis, and metabolic imbalance. These alterations promote cognitive decline and disease progression, while circadian biomarkers and chronotherapeutic interventions offer opportunities for precision diagnosis ...
Bivek Singh, Filippo Pigazzani, Roberto Manfredini   +2 more
wiley   +1 more source

Lecanemab over a two-year duration: Key insights from a regional specialty medical center

The Journal of Prevention of Alzheimer's Disease
Background and objectives: The anti-amyloid monoclonal antibody lecanemab (Leqembi®) treats patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).
Lisa B.E. Shields, Hannah S. Hust, Gregory E. Cooper, Theresa Kluthe, Rachel N. Hart, Andrew P. Thaliath, Brandon C. Dennis, Stephanie W. Freeman, Jessica F. Cain, Whoy Y. Shang, Kendall M. Wasz, Adam T. Orr, Christopher B. Shields, Shirish S. Barve, Kenneth G. Pugh   +14 more
doaj   +1 more source

Effectiveness of Lecanemab on Alzheimer’s Disease

Precision Nanomedicine
<img src=” https://s3.amazonaws.com/production.scholastica/article/92098/large/prnano_1142023_background_image.jpg?1704732136”> Alzheimer’s disease (AD) is a global public health crisis with a significant impact on individuals, families, and societies.
Flen John Thomas, Mohammad Aamir Qayyum Sarguroh Khan, Ramlah Atif Khan, Sarthak Vasantkumar Patel   +3 more
openaire   +2 more sources

Lecanemab en la enfermedad de Alzheimer

Acta Neurológica Colombiana
La hipótesis amiloide, que propone la acumulación del péptido ?-amiloide (?A) en la sinapsis, es el factor clave de la patogénesis de la enfermedad de Alzheimer (EA) y esta ha sido la idea dominante en el campo de la investigación de la EA durante casi ...
Paulina Elizabeth Bombón Albán, Johanna Vanessa Suárez Salazar, Lennyn Estuardo Albán León   +2 more
doaj   +1 more source

Multimerization of a rationally designed nanobody for enhanced avidity toward Aβ42 oligomers

Protein Science, Volume 35, Issue 9, September 2026.
Abstract Alzheimer's disease affects tens of millions of people worldwide and is associated with the self‐assembly of the Aβ42 peptide into amyloid aggregates. Among the species formed during this process, soluble oligomeric intermediates are the most closely linked to neurotoxicity and are therefore an attractive target for both therapeutic and ...
Magdalena Nowinska, Elijah Suh, Casey Mogilevsky, Michele Vendruscolo   +3 more
wiley   +1 more source

Novel Therapeutic Insights Into Alzheimer's Disease: Glymphatic System and Meningeal Lymphatic Vessels

Aging Cell, Volume 25, Issue 9, September 2026.
The identification of the glymphatic system (GS) and meningeal lymphatic vessels (mLVs) challenges the century‐old “immune‐privileged” dogma of the central nervous system (CNS), establishing a critical mechanistic link between impaired waste clearance (Aβ/tau) and the pathogenesis of Alzheimer's disease (AD).
Bingbing Song, Wei Wang, Siqi Liu, Xi Jin, Yan Qi, Mingquan Li, Dongjie Yue, Yu Liu, Xiangqi Li, Lei Yin, Lina Feng   +10 more
wiley   +1 more source

Krankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-Demenz

Zusammenfassung Die Alzheimer Krankheit (AD) ist eine schwere und fortschreitende neurodegenerative Erkrankung des Gehirns, die bislang mit primär nur symptomatisch wirksamen medikamentösen und nicht-medikamentösen Therapieformen als Standardtherapie ...
Hansen, Niels, Wiltfang, Jens
core   +1 more source